Table 2.

Molecular Characteristics of Post-Crizotinib Biopsies and Individual Responses to Crizotinib and Ceritinib

Patient	Crizotinib PFS (m)	Crizotinib Beyond Progression (m)	ALK Resistance Mutations or Amplification in Crizotinib-Resistant Biopsy	Interval Lines of Therapy	Crizotinib-Ceritinib Interval (m)	Ceritinib PFS (m)
1	18.2	0.4	C1156Y	0	0.3	2.4
2	4.6	1.6	ALK Amplification	0	0.8	4.3
3	7.5	3.4	L1196M	0	0.7	3.9
4	11.2	0.8	NM	2	4.4	8.2
5	32	3.3	S1206Y	0	0.8	14.8
6	6.1	5.4	NM	0	0.5	9.7
7	18.5	9.2	NM	0	0.3	16.2*
8	8.1	5.2	L1196M	1	11.0	10.8
9	6.9	2.1	NM	2	10.2	11.3
10	9.8	0.0	NM	0	2.0	18.0
11	14.5	0.0	L1196M	0	0.6	5.4
12	7.4	1.0	ALK Amplification	0	0.9	9.5
13	13.5	0.1	NM	0	1.6	5.2
14	3.1	2.5	NM	0	0.3	1.2
15	2.6	0.2	NM	0	0.5	6.5
16	8.1	0.0	NM	1	15.7	2.7
17	10.8	2.0	G1269A, 1151Tins	1	3.6	2.7
18	7.1	1.3	NM	0	0.3	2.9
19	2.8	1.4	NM	1	1.5	1.8
20	5.6	1.5	NM	0	0.3	4.0
21	20.6	0.0	NM	3	23.1	8.2
22	20.4	7.4	NM	0	0.5	16.8
23	11.5	1.0	L1196M	0	0.8	8.9

Abbreviations: M, months; NM, no ALK resistance mutation;

^*Censored